Search

Your search keyword '"Gaudy C"' showing total 9 results
Start Over Author "Gaudy C" Publication Year Range Last 3 years
9 results on '"Gaudy C"'

2. The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns

Author

Amini-Adle, M., primary, Arnault, J.-P., additional, Aubin, F., additional, Beneton, N., additional, Bens, G., additional, Brunet-Possenti, F., additional, Célerier, P., additional, Charles, J., additional, Crumbach, L., additional, Dalac, S., additional, Darras, S., additional, De Quatrebarbes, J., additional, Dinulescu, M., additional, Dutriaux, C., additional, Gaudy, C., additional, Gérard, E., additional, Giacchero, D., additional, Granel-Brocard, F., additional, Grange, F., additional, Jouary, T., additional, Kramkimel, N., additional, Lebbé, C., additional, Le Corre, Y., additional, Legoupil, D., additional, Lesage, C., additional, Lesimple, T., additional, Lorphelin, J.-M., additional, Mansard, S., additional, Martin, L., additional, Mary-Prey, S., additional, Maubec, E., additional, Meyer, N., additional, Mignard, C., additional, Montaudie, H., additional, Mortier, L., additional, Nardin, C., additional, Neidhardt Berard, E.-M., additional, Pagès Laurent, C., additional, Peuvrel, L., additional, Quereux, Gaelle, additional, Robert, Caroline, additional, Saiag, Philippe, additional, Saint-Jean, Mélanie, additional, Samimi, M., additional, Sassolas, B., additional, Scalbert, C., additional, Skowron, F., additional, Steff, M., additional, Stoebner, P.-E., additional, Trablesi, S., additional, Visseaux, L., additional, Zehou, O., additional, and Boespflug, A., additional

Published
2024
Full Text
View/download PDF

5. Continuing Professional Development Model in the Schools Division of Sarangani

Author

Roy Tribunalo and Gaudy C. Ortizo

Abstract

This study explored and determined the extent of the Continuing Professional Development (CPD) implementation in government school institutions in the Sarangani Division for School Year 2022-2023. The 375 respondents from a total population of 6, 042 public school teacher were randomly selected across the 23 school districts. Based on the findings, the hypothesis on no significant relationship between the extent of the CPD implementation and the teacher’s competencies is accepted because of the Pearson’s r-value of -0.081 with negligible correlation 0.118 p-value. However, the hypothesis on no significant relationship between the contributing factors and the extent of CPD implementation is rejected and the model is a partial mediation. Sobel test yielded a z-value of -3.10600817 with a p-value of 0.00189631 that means significant at 0.05 level. Further, three major themes surfaced from the informant’s in-depth interview after an intensive analysis of the data gathered, namely: Limited Training Offered, Insufficient Execution of the Program, and Participatory Barriers to CPD Training. The indicated training need, preferred CPD modalities and pace, as well as monitoring, evaluation, and offering technical support to schools in terms of CPD may be taken into consideration by DepEd Offices. Hence, a CPD Model is recommended to take effect in the Schools Division of Sarangani to address the actual competency gap and relevant training needs for teachers’ professional growth and development.

Published
2023

7. First cases of Omicron in France are exhibiting mild symptoms, November 2021–January 2022

Author

Andrieu, A., Broustal, O., Chene, S., Chent, S., Fougère, E., Gbaguidi, G., Hamidouche, M., Lamy, A., Mano, Q., Mastrovito, B., Mercier, A., Modenesi, G., Picard, G., Prudhomme, J., Rapilly, F., Riondel, A., Rivière, M., Villegas Ramirez, B., Zhu-Soubise, A., Zurbaran, M., Amzert, A., Andreoletti, L., Bal, A., Beaurepere, R., Behillil, S., Belec, L., Bernard, C., Bocket, L., Bouri, L., Bourlet, T., Bressollette-Bodin, C., Brichler, S., Brugerolles, C., Cado, S., Calvez, V., Capron, N., Castelain, S., Castro-Alvarez, J., Chaix, M.-L., Charpentier, C., Che, D., Chillou, C., Colson, P., Coudene, P., Crinquette, A., De Rougemont, A., Delagrèverie, H., Delamare, C., Denecker-Berardino, T., Descamps, D., Desroches, M., Destras, G., Dos Santos, G., Ducancelle, A., Ducreux, S., Duret, T., Enouf, V., Fafi-Kremer, S., Felici, C., Fourati, S., Fournier, P.-E., Gaudy, C., Germain, H., Giordanengo, V., Gorge, O., Haim-Boukobza, S., Henquell, C., Holstein, A., Houhamdi, L., Izopet, J., Jacomo, V., Jacques, A., Jaffar-Bandjee, M.-C., Jimenez, M., Josset, L., Kemeny, S., Lafon, M.-E., Le Bars, A., Le Corguille, G., Lepiller, Q., Levasseur, A., Leveque, N., Lina, B., Madelaine, C., Malabat, C., Marque-Juillet, S., Martin-Dunavit, T., Mavingui, P., Merens, A., Messak, I., Morand-Joubert, L., Naudot, X., Neybecker, P., Pawlotsky, J.-M., Pilorge, L., Plantier, J.-C., Poggi, C., Pretet, M., Ragot, C., Raoul, H., Rogez, S., Roque-Afonso, A.-M., Roquebert, B., Rousset, D., Rozenberg, F., Sagot, C., Sahnoune, S., Salgado, D., Sand, O., Saudemont, C., Schvoerer, E., Simon-Loriere, E., Stephan, R., Sudour, J., Thibault, V., Tuaillon, E., Vabret, A., Vallee, E., Van Der Werf, S., Van Helden, J., Verdurme, L., Vignola, A., Wilkinson, D., Yazdanpanah, Y., Maisa, A., Spaccaferri, G., Fournier, L., Schaeffer, J., Deniau, J., Rolland, P., and Coignard, B.

Published
2022
Full Text
View/download PDF

8. First cases of Omicron in France are exhibiting mild symptoms, November 2021–January 2022

Author

Maisa, A., primary, Spaccaferri, G., additional, Fournier, L., additional, Schaeffer, J., additional, Deniau, J., additional, Rolland, P., additional, Coignard, B., additional, Andrieu, A., additional, Broustal, O., additional, Chene, S., additional, Chent, S., additional, Fougère, E., additional, Gbaguidi, G., additional, Hamidouche, M., additional, Lamy, A., additional, Mano, Q., additional, Mastrovito, B., additional, Mercier, A., additional, Modenesi, G., additional, Picard, G., additional, Prudhomme, J., additional, Rapilly, F., additional, Riondel, A., additional, Rivière, M., additional, Villegas Ramirez, B., additional, Zhu-Soubise, A., additional, Zurbaran, M., additional, Amzert, A., additional, Andreoletti, L., additional, Bal, A., additional, Beaurepere, R., additional, Behillil, S., additional, Belec, L., additional, Bernard, C., additional, Bocket, L., additional, Bouri, L., additional, Bourlet, T., additional, Bressollette-Bodin, C., additional, Brichler, S., additional, Brugerolles, C., additional, Cado, S., additional, Calvez, V., additional, Capron, N., additional, Castelain, S., additional, Castro-Alvarez, J., additional, Chaix, M.-L., additional, Charpentier, C., additional, Che, D., additional, Chillou, C., additional, Colson, P., additional, Coudene, P., additional, Crinquette, A., additional, De Rougemont, A., additional, Delagrèverie, H., additional, Delamare, C., additional, Denecker-Berardino, T., additional, Descamps, D., additional, Desroches, M., additional, Destras, G., additional, Dos Santos, G., additional, Ducancelle, A., additional, Ducreux, S., additional, Duret, T., additional, Enouf, V., additional, Fafi-Kremer, S., additional, Felici, C., additional, Fourati, S., additional, Fournier, P.-E., additional, Gaudy, C., additional, Germain, H., additional, Giordanengo, V., additional, Gorge, O., additional, Haim-Boukobza, S., additional, Henquell, C., additional, Holstein, A., additional, Houhamdi, L., additional, Izopet, J., additional, Jacomo, V., additional, Jacques, A., additional, Jaffar-Bandjee, M.-C., additional, Jimenez, M., additional, Josset, L., additional, Kemeny, S., additional, Lafon, M.-E., additional, Le Bars, A., additional, Le Corguille, G., additional, Lepiller, Q., additional, Levasseur, A., additional, Leveque, N., additional, Lina, B., additional, Madelaine, C., additional, Malabat, C., additional, Marque-Juillet, S., additional, Martin-Dunavit, T., additional, Mavingui, P., additional, Merens, A., additional, Messak, I., additional, Morand-Joubert, L., additional, Naudot, X., additional, Neybecker, P., additional, Pawlotsky, J.-M., additional, Pilorge, L., additional, Plantier, J.-C., additional, Poggi, C., additional, Pretet, M., additional, Ragot, C., additional, Raoul, H., additional, Rogez, S., additional, Roque-Afonso, A.-M., additional, Roquebert, B., additional, Rousset, D., additional, Rozenberg, F., additional, Sagot, C., additional, Sahnoune, S., additional, Salgado, D., additional, Sand, O., additional, Saudemont, C., additional, Schvoerer, E., additional, Simon-Loriere, E., additional, Stephan, R., additional, Sudour, J., additional, Thibault, V., additional, Tuaillon, E., additional, Vabret, A., additional, Vallee, E., additional, Van Der Werf, S., additional, Van Helden, J., additional, Verdurme, L., additional, Vignola, A., additional, Wilkinson, D., additional, and Yazdanpanah, Y., additional

Published
2022
Full Text
View/download PDF

9. Effective Anti-SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders.

Author

Rossignol J, Ouedrani A, Livideanu CB, Barete S, Terriou L, Launay D, Lemal R, Greco C, Frenzel L, Meni C, Bodemere-Skandalis C, Polivka L, Collange AF, Hachichi H, Bouzourine S, Messaoud DN, Negretto M, Vendrame L, Jambou M, Gousseff M, Durupt S, Lega JC, Durand JM, Gaudy C, Damaj G, Gourin MP, Hamidou M, Bouillet L, Le Mouel E, Maria A, Zunic P, Cabrera Q, Vincent D, Lavigne C, Riviere E, Gourguechon C, Courbebaisse M, Lebeaux D, Parfait B, Friedlander G, Brignier A, Lhermitte L, Molina TJ, Bruneau J, Agopian J, Dubreuil P, Ranta D, Mania A, Arock M, Staropoli I, Tournilhac O, Lortholary O, Schwartz O, Chatenoud L, and Hermine O

Subjects
Antibodies, Viral, Antiviral Agents, Humans, Immunity, Mast Cells, SARS-CoV-2, COVID-19, Mastocytosis
Abstract

Background: Mast cells are key players in innate immunity and the T H 2 adaptive immune response. The latter counterbalances the T H 1 response, which is critical for antiviral immunity. Clonal mast cell activation disorders (cMCADs, such as mastocytosis and clonal mast cell activation syndrome) are characterized by abnormal mast cell accumulation and/or activation. No data on the antiviral immune response in patients with MCADs have been published., Objective: To study a comprehensive range of outcomes in patients with cMCAD with PCR- or serologically confirmed coronavirus disease 2019 and to characterize the specific anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune response in this setting., Methods: Clinical follow-up and outcome data were collected prospectively over a 12-month period by members of the French Centre de Référence des Mastocytoses rare disease network. Anti-SARS-CoV-2-specific T-cell activity was measured with an ELISA, and humoral responses were evaluated by assaying circulating levels of specific IgG, IgA, and neutralizing antibodies., Results: Overall, 32 patients with cMCAD were evaluated. None required noninvasive or mechanical ventilation. Two patients were admitted to hospital for oxygen and steroid therapy. The SARS-CoV-2-specific immune response was characterized in 21 of the 32 patients. Most had high counts of circulating SARS-CoV-2-specific, IFN-γ-producing T cells and high titers of neutralizing antispike IgGs. The patients frequently showed spontaneous T-cell IFN-γ production in the absence of stimulation; this production was correlated with basal circulating tryptase levels (a marker of the mast cell burden)., Conclusions: Patients with cMCADs might not be at risk of severe coronavirus disease 2019, perhaps due to their spontaneous production of IFN-γ., (Copyright © 2022. Published by Elsevier Inc.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results